Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 2023 Wells Fargo Healthcare Conference Transcript September 6, 2023 8:45 AM ET Executives Marion McCourt – Head, Commercial Ryan Crowe – Head, Investor Relations Analysts Mohit Bansal – Wells Fargo Mohit Bansal Good morning. My name is Mohit Bansal. I am one of the Biopharma Analysts here at Wells Fargo and I am very happy to start with Regeneron Pharmaceuticals today. We have Marion McCourt, Head of Commercial at Regeneron; and Ryan Crowe, Head of Investor Relations. Thank you very much for joining us. Over to you, Ryan. Ryan Crowe Thanks, Mohit, and it’s great to be here. I always love coming to this conference. It’s our second year in a row here and I am very excited to be here again. I’d like to remind you that our remarks today may include forward-looking statements about Regeneron. Each forward-looking statement is subject to risks and uncertainties […]

Regeneron Pharmaceuticals (NASDAQ:REGN) reported Q2 non-GAAP earnings  of $10.24 diluted share, up from $9.77 a year earlier. Analysts polled by Capital IQ expected $9.90. Revenue for the quarter ended June 30 was $3.16 billion, up from $2.86 billion a year earlier. Analysts surveyed by Capital IQ expected $3.02 billion. The company now anticipates 2023 capital expenditures in the range of $760 million to $830 million versus its previous guidance of $800 million to $900 million.